Member Info for EmeraldCarrots

Profiling. First time Angle have promoted this after Astrazeneca paid them £670,000 to develop it I think. RNS to says it was done was end March 2025. Any Co. in the World that wants to use it in a cancer grugs trial please contact Angle Plc !!!

"ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profiling".

This work demonstrates how ANGLE's Portrait AR workflow enables sensitive, real-time monitoring of AR expression from a simple blood draw. The assay is now available as part of ANGLE's assay menu to support pharma customers with longitudinal biomarker assessment in AR-targeted clinical trials.". Astrazeneca paid £670,000 for this assay development. Will they uses it in a trial or now? If they do then Angle's sp will rocket. If another Plc does ditto. It's only been availiable for about 3 months so we wait............

https://www.lse.co.uk/rns/AGL/eacr-2025-innovation-in-ar-expression-profiling-822fhickzn907qc.html

L2 would be nice.

Will be interesting.

All IMHO.

People who have cancer that has metastasized (spread) could be tested to hopefully find cancer biomarkers that mean they qualify for some targeted cancer treatments. With dual analysis their would be about twice the chance of finding said biomarkers. This has obviously got Illumina's attention.

All IMHO.

The statistics of using the Illumina assay. "This study demonstrates ANGLE's unique ability to deliver DNA dual analysis from a single blood sample, revealing clinically relevant mutations missed by ctDNA alone. By enabling a more complete view of tumour genetics, molecular analysis of CTC-DNA and ctDNA using the Parsortix system offers biopharma partners a valuable tool for identifying resistance, stratifying patients, and improving trial outcomes."

Https://www.lse.co.uk/rns/AGL/eacr-2025-data-demonstrating-dna-dual-analysis-9218c5p5cpg3ebn.html

============

"Androgen Receptor EXPRESSION profiling"

This work demonstrates how ANGLE's Portrait AR workflow enables sensitive, real-time monitoring of AR expression from a simple blood draw. The assay is now available as part of ANGLE's assay menu to support pharma customers with longitudinal biomarker assessment in AR-targeted clinical trials.". Astrazeneca paid £670,000 for this assay development. Will they uses it in a trial or now? If they do then Angle's sp will rocket. If another Plc does ditto. It's only been availiable for about 3 months so we wait............

https://www.lse.co.uk/rns/AGL/eacr-2025-innovation-in-ar-expression-profiling-822fhickzn907qc.html

Up 3.23% already.

Https://www.lse.co.uk/rns/AGL/eacr-2025-data-demonstrating-dna-dual-analysis-9218c5p5cpg3ebn.html

https://www.lse.co.uk/rns/AGL/eacr-2025-innovation-in-ar-expression-profiling-822fhickzn907qc.html

Sp up 6.9% too.......

Huge trades.

Up 6.9%.

Up 6.9%,

Small ish trades though.

Ask up to 8p, up 3.45%. Astrazeneca news?, Illumina news?, or based on jack *hit, who knows, LOL!!!

Could be anything!

Can find about twice as many biomarkers as CtDna analysis alone (independently confirmed). Angle of course discovered this (see RNS dated 4th January 2024). If this were not the case and we were waiting for Astrazeneca to decide whether to actually use the Androgen Receptor assay in a trial, or the DNA damage response assay then things would be worse. At first glance they seem very important. But there is no guarantee Astrazeneca will use them. Also huge Pharma Companies take many months to make decisions to do with cancer drug trials. It is incredibly slow. It's only been about three months since Angle got the Astrazenica assays signed off.

The obvious and most promising source of substantial income is dual analysis in my view. Illumina clearly think it will be a commercial success, or they would not have helped Angle Plc develop the first lung cancer version. Hopefully, once the "off the shelf" kit is available and dare I say advertised on Illumina’s web site Angle will have finally arrived.

All IMHO.

Is confirmed. Hope the performance is better than updating their web site that took the almost a week. Although maybe it is updated by a Co. they employ and that could be the reason I suppose.

Can find about twice as many biomarkers as CtDna analysis alone (independently confirmed). If this were not the case and we were waiting for Astrazeneca to decide whether to actually use the Androgen Receptor assay in a trial, or the DNA damage response assay then things would be worse. At first glance they seem very important. But there is no guarantee Astrazeneca will use them.

The obvious and most promising source of substantial income is dual analysis in my view. Illumina clearly think it will be a commercial success, or they would not have helped Angle develop the first lung cancer version. Hopefully, once the "off the shelf" kit is available and dare I say advertised on Illumina’s web site Angle will have finally arrived.

All IMHO.

I think Asrazeneca would be wise to avoid investing in China. I thought B.P and Shell investing in Russia was foolish and look happened there. Short term finacial gain and then disaster.

All IMHO.

I can't see them dropping heavy hints in the half year report about increased sales in the EU (now there are 15,000 more hosoitals to sell to) unless they had a very good idea about demand. As soon as we get an RNS about a single new client in the EU (***now we have the CE mark***) the sp will take off. Bye bye 2p.

All IMHO.

Suppse you won't qualify to apply for any. I suspect we will get some positive RNS's about international sales, then of course the sp might be over 2p. Then what? Place 'yer bets!